
MannKind is a biotechnology business based in the US. MannKind shares (MNKD) are listed on the NASDAQ and all prices are listed in US Dollars. MannKind employs 348 staff and has a trailing 12-month revenue of around $76.2 million.
How to buy MannKind stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – MNKD. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
MannKind stock price (NASDAQ: MNKD)
Use our graph to track the performance of MNKD stocks over time.MannKind shares at a glance
Latest market close | $5.15 |
---|---|
52-week range | $2.49 - $5.47 |
50-day moving average | $4.76 |
200-day moving average | $3.92 |
Wall St. target price | $6.10 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.38 |
Buy MannKind stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy MannKind stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
MannKind price performance over time
Historical closes compared with the close of $5.15 from 2023-01-30
1 week (2023-01-25) | -2.83% |
---|---|
1 month (2022-12-30) | -2.28% |
3 months (2022-11-01) | 48.41% |
6 months (2022-08-01) | 43.85% |
1 year (2022-02-01) | 36.24% |
---|---|
2 years (2021-02-01) | 41.10% |
3 years (2020-01-31) | 250.34% |
5 years (2018-02-01) | 97.32% |
MannKind financials
Revenue TTM | $76.2 million |
---|---|
Gross profit TTM | $36.6 million |
Return on assets TTM | -20% |
Return on equity TTM | 0% |
Profit margin | -127.93% |
Book value | $-0.90 |
Market capitalisation | $1.4 billion |
TTM: trailing 12 months
MannKind share dividends
We're not expecting MannKind to pay a dividend over the next 12 months.
Have MannKind's shares ever split?
MannKind's shares were split on a 1:5 basis on 2 March 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MannKind shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for MannKind shares which in turn could have impacted MannKind's share price.
MannKind share price volatility
Over the last 12 months, MannKind's shares have ranged in value from as little as $2.49 up to $5.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MannKind's is 1.6714. This would suggest that MannKind's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MannKind overview
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. .
MannKind in the news
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
Frequently asked questions
What percentage of MannKind is owned by insiders or institutions?Currently 6.184% of MannKind shares are held by insiders and 50.403% by institutions. How many people work for MannKind?
Latest data suggests 348 work at MannKind. When does the fiscal year end for MannKind?
MannKind's fiscal year ends in December. Where is MannKind based?
MannKind's address is: 30930 Russell Ranch Road, Westlake Village, CA, United States, 91362 What is MannKind's ISIN number?
MannKind's international securities identification number is: US56400P7069 What is MannKind's CUSIP number?
MannKind's Committee on Uniform Securities Identification Procedures number is: 56400P201
More guides on Finder
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert